Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)

 Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)

Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESCO 2018

Shots:

  • The P-III KATHERINE study assessed Kadcyla vs Herceptin (trastuzumab) as an adjuvant therapy for patients with HER2-positive eBC for three years
  • P-III KATHERINE study results: risk of disease recurrence or death 50%; didn’t have breast cancer return (88.3% vs 77.0%); with no new safety issues
  • Kadcyla is an antibody-drug conjugate (ADC) developed for delivering CT directly to HER2-positive cancer cells and is approved in 104 countries including the US and EU for HER2-positive metastatic breast cancer

Click here to read full press release/ article | Ref: Roche | Image: Roche

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post